Dr Rifkin on the Evaluation of Prophylactic Tocilizumab Prior to Teclistamab in R/R Myeloma

Поделиться
HTML-код
  • Опубликовано: 25 июн 2024
  • Robert M. Rifkin, MD, FACP, discusses the use of prophylactic tocilizumab to reduce teclistamab-related CRS in relapsed/refractory myeloma.

Комментарии •